Complete financial analysis of Elevai Labs, Inc. Common Stock (ELAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevai Labs, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Meritage Homes Corporation (MTH) Income Statement Analysis – Financial Results
- Greystone Logistics, Inc. (GLGI) Income Statement Analysis – Financial Results
- Hurxley Corporation (7561.T) Income Statement Analysis – Financial Results
- Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) Income Statement Analysis – Financial Results
- FAMILY CARE HOSPITALS LIMITED (FAMILYCARE.BO) Income Statement Analysis – Financial Results
Elevai Labs, Inc. Common Stock (ELAB)
Industry: Biotechnology
Sector: Healthcare
About Elevai Labs, Inc. Common Stock
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 1.71M | 766.28K | 827.00 | 0.00 |
Cost of Revenue | 578.02K | 324.00K | 2.85K | 0.00 |
Gross Profit | 1.13M | 442.28K | -2.02K | 0.00 |
Gross Profit Ratio | 66.25% | 57.72% | -244.01% | 0.00% |
Research & Development | 426.24K | 228.75K | 123.63K | 118.86K |
General & Administrative | 3.37M | 1.54M | 602.73K | 95.94K |
Selling & Marketing | 660.29K | 192.86K | 31.61K | 6.08K |
SG&A | 4.03M | 1.80M | 633.96K | 102.99K |
Other Expenses | -3.32M | -198.44K | -25.45K | 0.00 |
Operating Expenses | 1.13M | 2.23M | 783.04K | 222.91K |
Cost & Expenses | 5.47M | 2.55M | 785.89K | 222.91K |
Interest Income | 5.56K | 7.70K | 0.00 | 0.00 |
Interest Expense | 19.53K | 2.63K | 0.00 | 0.00 |
Depreciation & Amortization | 11.65K | 6.51K | 2.76K | 221.84K |
EBITDA | -4.27M | -1.78M | -782.30K | -1.07K |
EBITDA Ratio | -249.35% | -232.52% | -94,594.92% | 0.00% |
Operating Income | -3.67M | -1.79M | -785.06K | -221.84K |
Operating Income Ratio | -214.24% | -233.37% | -94,928.66% | 0.00% |
Total Other Income/Expenses | -632.45K | -11.98K | 321.00 | -1.07K |
Income Before Tax | -4.30M | -1.80M | -784.74K | -222.91K |
Income Before Tax Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
Income Tax Expense | 0.00 | -2.00 | 3.00 | -1.07K |
Net Income | -4.30M | -1.80M | -784.74K | -222.91K |
Net Income Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
EPS | -0.40 | -0.19 | -0.05 | -0.05 |
EPS Diluted | -0.40 | -0.19 | -0.05 | -0.05 |
Weighted Avg Shares Out | 10.75M | 9.53M | 17.33M | 4.41M |
Weighted Avg Shares Out (Dil) | 10.75M | 9.53M | 17.33M | 4.41M |
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
CORRECTION - Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
Source: https://incomestatements.info
Category: Stock Reports